Key result
Valve-sparing operations using the Gelweave Valsalva prosthesis demonstrated an in-hospital mortality of 4.7% and a 3-year freedom from grade 3-4 aortic insufficiency of 91.7%.
Why the study?
Does the Gelweave Valsalva prosthesis provide good clinical outcomes and valve durability in patients undergoing aortic valve-sparing operations?
Cohort (n=63)
Does the Gelweave Valsalva prosthesis provide good clinical outcomes and valve durability in patients undergoing aortic valve-sparing operations?
The Gelweave Valsalva prosthesis demonstrates good early to mid-term clinical outcomes with high freedom from significant aortic insufficiency and reoperation at 3 years in patients undergoing aortic valve-sparing operations.
Supports Gelweave Valsalva use in valve-sparing aortic surgery; leaves open need for randomized durability comparisons.
Aortic valve-sparing operations have provided very good clinical outcomes. However, the absence of the sinuses of Valsalva might limit valve durability. The Gelweave Valsalva prosthesis, which presents pre-fashioned neo-sinuses, has been designed in order to avoid early leaflets deterioration. We report our results in 63 patients who underwent valve-sparing operations (reimplantation technique) using the Gelweave Valsalva graft. The main indication was ascending aorta aneurysm or annuloaortic ectasia, with or without aortic insufficiency. The operation was performed also in cases of Marfan syndrome, Bicuspid Aortic Valve (BAV), and acute Type A dissection. In-hospital mortality was of 4.7%, and two thirds were acute Type A dissection patients (P=0.01). There were no late deaths. Three years freedom from grade 3-4 AI and freedom from late aortic valve replacement were 91.7+/-4.3% and 93.8+/-5.1%, respectively. Aortic valve-sparing operations show good results in patients electively operated for aortic root ectasia. Aortic cusps repair may lead to late failure. Even if the Gelweave Valsalva prosthesis is easy to implant and it also reproduces pseudosinuses, a long-term follow up is necessary to determine if this graft may reduce leaflets deterioration.
No takes yet. Share an insight, caveat, or question.
Roberto Di Bartolomeo (2006) conducted a cohort in Ascending aorta aneurysm or annuloaortic ectasia (n=63). Gelweave Valsalva prosthesis was evaluated on In-hospital mortality. Valve-sparing operations using the Gelweave Valsalva prosthesis demonstrated an in-hospital mortality of 4.7% and a 3-year freedom from grade 3-4 aortic insufficiency of 91.7%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: